Thermo Fisher debuts hematology/oncology assays

By The Science Advisory Board staff writers

August 20, 2020 -- Thermo Fisher Scientific has debuted hematology/oncology assays that enable simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a day.

The Oncomine Myeloid Assay Gx is designed for Thermo Fisher's Ion Torrent Genexus system. The assay also enables researchers to profile 40 DNA targets and 29 fusion driver genes; this enables the detection of more than 600 fusion isotypes for identifying biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia, and myelodysplastic syndrome.

Thermo Fisher plans to roll out other assays for hematology/oncology clinical research, such as for B-cell and T-cell clonality and somatic hypermutation assessment using immune repertoire sequencing to study lymphoid malignancies.

Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...
Thermo Fisher posts 10% growth in Q2
Thermo Fisher Scientific reported financial results for the second quarter, noting 10% revenue growth.
Thermo Fisher expands COVID-19 therapies, vaccines
Thermo Fisher Scientific is expanding the development and production of COVID-19 vaccines, therapies, and additional treatments.
Thermo Fisher to develop, manufacture next-gen immunotherapy
Thermo Fisher Scientific has formed a strategic partnership with PharmAbcine for the development and manufacturing of PMC-309, a next-generation immune...
Thermo Fisher to operate new CSL biologics facility
Thermo Fisher Scientific has entered into a long-term lease agreement with CSL to operate a new biologics manufacturing facility in Lengnau, Switzerland.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter